Bristol-myers Squibb Compnay

Daniel F Ardourel

Paul O Sheppard

Brigitte Devaux

Mark J Selby

Alan J Korman

Guodong Chen

Michelle Minhua Han

Huiming Li

Ekaterina G Deyanova

Xiao Min Schebye

Christine Bee

Andy X Deng

Anan Chuntharapai

Richard Y Huang

Michelle Renee Kuhne

Hong-An Truong

Mohan Srinivasan

Mark F Maurer

Indrani Chakraborty

Tseng-hui Timothy Chen

Susan H Julien

Richard Yu-Cheng Huang

Hong-An Troung

Michelle Kuhne

Tseng-Hui Timothy Chen

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

Growing community of inventors

Woodinville, WA, United States of America

Daniel F Ardourel